ABSTRACT
OBJECTIVE: To determine the association of serum monocyte chemoattractant protein-1 (MCP-1) concentration and clinical variables of antiphospholipid syndrome (APS). METHODS: We investigated the serum concentration of MCP-1 in systemic lupus erythematosus (SLE) patients by ELISA. The clinical features of APS were evaluated in SLE patients, and anticardiolipin antibody (aCL) was determined at the time of blood sampling. RESULTS: Serum MCP-1 levels (median [range]) in 76 SLE patients were significantly higher than those in 99 healthy controls (192 pg/ml [116, 560] versus 91 pg/ml [26~251], p3 years) had higher levels of MCP-1 than those without (263 pg/ml [166,534] versus 196 pg/ml [116,322], P=0.023). Furthermore, serum MCP-1 levels correlated well with IgG aCL titers (r=0.62, p<0.001). CONCLUSION: Serum MCP-1 levels were elevated in SLE patients, particularly in those with APS, and correlated well with titers of IgG aCL and thrombosis. Our data suggest that increased MCP-1 may play a critical role in the development of APS in SLE patients.
Subject(s)
Humans , Antibodies, Anticardiolipin , Antiphospholipid Syndrome , Chemokine CCL2 , Enzyme-Linked Immunosorbent Assay , Immunoglobulin G , Lupus Erythematosus, Systemic , Monocytes , ThrombosisABSTRACT
OBJECTIVE: To investigate the dosage of bovine type II collagen (BnCII) for the induction of oral tolerance in CIA animals, and to verify the changes of immune response and TGF-beta production of mesenteric lymph node cells in tolerized CIA animals. METHODS: Oral tolerance was induced by feeding of variable doses (5 microgram, 10 microgram, 20 microgram and 40 microgram) of BnCII to DBA/1 mice 4 times per week during 2 weeks, and control mice were given ovalbumin (1000 microgram), before immunization. We examed clinical assessment ; incidence of arthritis, severity of arthritis, arthritic limb by visual analysis. IgG antibodies to BnCII were measured by ELISA, T cell responses to BnCII and PHA were quantified by antigen (CII)-induced 3H-thymidine incorporation into lymphocytes of mesenteric lymph node, draining lymph node, and spleen. TGF-beta in supernatants obtained from lymph node culture medium was measured by ELISA. RESULTS: Arthritis limbs were observed in 100% of control at 5 weeks after subcutaneous BnCII injection. The incidences of CIA in all tolerized group were significantly lower than that in control 5 weeks after immunization (control 100 % vs. 5 microgram feeding group: 50%, 10 microgram feeding group: 50%, 20 microgram feeding group: 50%, 40 microgram feeding group: 55.5%, P<0.01). In comparison to control, mean articular indices were lower in all tolerized groups (control 5.13 : 5 microgram feeding group 3.50, 10 microgram feeding group 2.75, 20 microgram feeding group 2.87, 40 microgram feeding group 2.63, P<0.05). Arthritic limbs were also significantly lower in tolerized groups (control 58.3 : 5 microgram feeding group 20.8, 10 microgram feeding group 16.7, 20 microgram feeding group 20.8, 40 microgram feeding group 20.8, P<0.05). The titers of IgG antibody to CII were lower in tolerized group than that in control [tolerized group ; median 10 (min. 0, max. 48), control ; median 33 (min. 8.6, max. 101), P<0.05]. The proliferative responses to BnCII were significantly suppressed in tolerized (control 8010+/-2319cpm, tolerized group 4500+/-2060cpm, P<0.01). High TGF-beta production was noted in tolerized group (control ; 28pg/ml, BnCII feeding group ; 73pg/ml). CONCLUSION: Oral tolerance in DBA/1 mice was successfully induced from low doses of BnCII (5 microgram) and suppressed T and B cell function in conjunction with increased TGF-beta production may play an important role for the induction of CII induced oral tolerance in DBA/1 mice.
Subject(s)
Animals , Mice , Antibodies , Arthritis , Arthritis, Experimental , Collagen Type II , Enzyme-Linked Immunosorbent Assay , Extremities , Immunization , Immunoglobulin G , Incidence , Lymph Nodes , Lymphocytes , Ovalbumin , Spleen , Transforming Growth Factor betaABSTRACT
OBJECTIVE: To investigate the dosage of bovine type II collagen (BnCII) for the induction of oral tolerance in CIA animals, and to verify the changes of immune response and TGF-beta production of mesenteric lymph node cells in tolerized CIA animals. METHODS: Oral tolerance was induced by feeding of variable doses (5 microgram, 10 microgram, 20 microgram and 40 microgram) of BnCII to DBA/1 mice 4 times per week during 2 weeks, and control mice were given ovalbumin (1000 microgram), before immunization. We examed clinical assessment ; incidence of arthritis, severity of arthritis, arthritic limb by visual analysis. IgG antibodies to BnCII were measured by ELISA, T cell responses to BnCII and PHA were quantified by antigen (CII)-induced 3H-thymidine incorporation into lymphocytes of mesenteric lymph node, draining lymph node, and spleen. TGF-beta in supernatants obtained from lymph node culture medium was measured by ELISA. RESULTS: Arthritis limbs were observed in 100% of control at 5 weeks after subcutaneous BnCII injection. The incidences of CIA in all tolerized group were significantly lower than that in control 5 weeks after immunization (control 100 % vs. 5 microgram feeding group: 50%, 10 microgram feeding group: 50%, 20 microgram feeding group: 50%, 40 microgram feeding group: 55.5%, P<0.01). In comparison to control, mean articular indices were lower in all tolerized groups (control 5.13 : 5 microgram feeding group 3.50, 10 microgram feeding group 2.75, 20 microgram feeding group 2.87, 40 microgram feeding group 2.63, P<0.05). Arthritic limbs were also significantly lower in tolerized groups (control 58.3 : 5 microgram feeding group 20.8, 10 microgram feeding group 16.7, 20 microgram feeding group 20.8, 40 microgram feeding group 20.8, P<0.05). The titers of IgG antibody to CII were lower in tolerized group than that in control [tolerized group ; median 10 (min. 0, max. 48), control ; median 33 (min. 8.6, max. 101), P<0.05]. The proliferative responses to BnCII were significantly suppressed in tolerized (control 8010+/-2319cpm, tolerized group 4500+/-2060cpm, P<0.01). High TGF-beta production was noted in tolerized group (control ; 28pg/ml, BnCII feeding group ; 73pg/ml). CONCLUSION: Oral tolerance in DBA/1 mice was successfully induced from low doses of BnCII (5 microgram) and suppressed T and B cell function in conjunction with increased TGF-beta production may play an important role for the induction of CII induced oral tolerance in DBA/1 mice.
Subject(s)
Animals , Mice , Antibodies , Arthritis , Arthritis, Experimental , Collagen Type II , Enzyme-Linked Immunosorbent Assay , Extremities , Immunization , Immunoglobulin G , Incidence , Lymph Nodes , Lymphocytes , Ovalbumin , Spleen , Transforming Growth Factor betaABSTRACT
Primary tumors of the heart are rare and the most are benign. Malignant tumors constitute less than 25% of primary cardiac tumors and angiosarcomas are the most commonly reported histologic type. At least 160 cases have been reported in the world, but no previous report in Korea. We reported a case of primary cardiac angiosarcoma located in right atrium.
Subject(s)
Heart , Heart Atria , Heart Neoplasms , Hemangiosarcoma , KoreaABSTRACT
Both duodenal ulcer and gastric cancer are common, and it is well known that the pathophysiology of the two is different. The presence of a duodenal ulcer is believed to protect against the development of a gastric malignancy. However gastric cancer may occur in the presence of active or chronic duodenal ulcer disease. Although rare in incidence of coexistence of duodenal ulcer and gastric cancer, physician must be alert to the strange association of duodenal ulcer and gastric cancer. Here, we present 3 cases with coexistence of duodenal ulcer and gastric cancer, diagnosed by endoscopy.
Subject(s)
Duodenal Ulcer , Endoscopy , Incidence , Stomach NeoplasmsABSTRACT
OBJECTIVES: To evaluate the efficacy, safety and pharmacokinetics of fi-cyclodextrin-piroxicam in patients with osteoarthritis of knee. METHODS: Thirty patients with osteoarthritis(28 women, 2 men) were enrolled in the study. fi-cyclodextrin-piroxicam 20mg was administered orally, once daily for 8 weeks. The indices of efficacy(evaluation of the pain, joint swelling, tenderness and functional limitation) were evaluated at 0,2,4,8 weeks. Piroxicam plasma concentrations were determined by HPLC over 24 hours in 4 healthy volunteers, and were compared with those of reference formulation. RESULTS: There were statistically significant improvement in the indices of efficacy between entry and end of the study. The majority of side effects were related to the gastrointestinal tract, but the symptoms were mild except 1 drop-out case. According to pharmacokinetic study, the bioavailability and absorption rate of piroxicam were improved in fi-cyclodextrin-piroxicam group. Peak plasma piroxicam concentrations were higher in fi-cyclodextrin-piroxicam group than were in reference group. CONCLUSIONS: fi-cyclodextrin-piroxicam is efficacious and well tolerated in patients with osteoarthritis. Because of its rapid absorption, good bioavailability and fewer gastrointestinal disturbance, it seems to be a useful drug for long-term management of osteoarthritis.